ZyVersa is developing two proprietary product platforms targeting renal and inflammatory diseases. Cholesterol Efflux MediatorTM VAR 200, designed to ameliorate...
WEST CHESTER, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology...
Topline data from Phase 2 SHINE trial in patients with mild-to-moderate Alzheimer's disease anticipated in mid 2024 Topline data from...
- Completed SNS-101 monotherapy dose escalation through 15 mg/kg with no dose limiting toxicities - - Expands patient cohort in...
– ARCALYST® (rilonacept) 2023 net product revenue grew ~90% year-over-year to $233.1 million (unaudited) – – ARCALYST 2024 net product...
ANN ARBOR, Mich.--(BUSINESS WIRE)--NSF, the leading global public health and safety organization, today announced the appointment of Dean Bergy and...
- Gilead Also Included on the Dow Jones Sustainability North America Index; Rankings Reflect Gilead's Ongoing Commitment to Corporate Responsibility...
Agreements Support the Upcoming Launch of VEVYE®NASHVILLE, Tenn.--(BUSINESS WIRE)--$HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that...
PillSafe® protects the patient with a patented, innovative pill distribution control system that improves dosage safety, prevents prescription drug misuse,...
NEWARK, CA / ACCESSWIRE / January 3, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh...
Dan Peisert Stepping Down as CEO Board member Heather Mason Appointed Interim CEO LAKE FOREST, Ill., Jan. 03, 2024 (GLOBE...
VANCOUVER, British Columbia, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that...
Scorpius subsidiary to manufacture novel biologic targeting substance use disorderDURHAM, N.C., Jan. 03, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE...
Additional Ewing Sarcoma Patient in Company’s Phase 1/2 Sarcoma Trial Achieves Partial Response; Objective Response Rate Among First-Relapse Ewing Patients...
ZUG, Switzerland and BOSTON, Jan. 03, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating...
AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases ABATE Phase 1b/2 AD...
WESTON, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company...
Live event and webcast scheduled for 7:00 p.m. ET / 4:00 p.m. PTWALTHAM, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) --...
TAMPA, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at...
7th Sachs Annual Neuroscience Innovation Forum13rd Annual LifeSci Advisors Corporate Access EventBiotech Showcase-2024 42nd Annual J.P. Morgan Healthcare ConferenceInvest Securities...